Irpagratinib

Irpagratinib (ABSK011) is an orally active FGFR4 inhibitor (IC50[1][2].

Product Specifications

CAS Number

[2230974-62-4]

Product Name Alternative

ABSK011

UNSPSC

12352005

Target

FGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/irpagratinib.html

Purity

99.63

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(C(OC)=CC(OC)=C1F)=C1C2=CC(C=N3)=C(C(N4CC(C)(C4)OC)=N2)N=C3N[C@H]5[C@H](CCOC5)NC(C=C)=O

Molecular Formula

C28H32F2N6O5

Molecular Weight

570.59

References & Citations

[1]Chen Z. Abstract LB-272: Discovery and characterization of a novel FGFR4 Inhibitor for the treatment of hepatocellular carcinoma[J]. Cancer Research, 2018, 78 (13_Supplement) : LB-272-LB-272.|[2]Zhang N, et al. Selective FGFR4 inhibitor Irpagratinib (ABSK011) exhibits broad synergistic and combinatory anti-tumor effects with other therapeutic agents in preclinical HCC models]. Cancer Research, 2024, 84 (6_Supplement) : 1228-1228.